Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes
Xue-Feng Bai, … , Pan Zheng, Yang Liu
Xue-Feng Bai, … , Pan Zheng, Yang Liu
Published May 15, 2003
Citation Information: J Clin Invest. 2003;111(10):1487-1496. https://doi.org/10.1172/JCI17656.
View: Text | PDF
Article Oncology

Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes

  • Text
  • PDF
Abstract

It is established that mutations in viral antigenic epitopes, or antigenic drifts, allow viruses to escape recognition by both Ab’s and T lymphocytes. It is unclear, however, whether tumor cells can escape immune recognition via antigenic drift. Here we show that adoptive therapy with both monoclonal and polyclonal transgenic CTLs, specific for a natural tumor antigen, P1A, selects for multiple mutations in the P1A antigenic epitope. These mutations severely diminish T cell recognition of the tumor antigen by a variety of mechanisms, including modulation of MHC:peptide interaction and TCR binding to MHC:peptide complex. These results provide the first evidence for tumor evasion of T cell recognition by antigenic drift, and thus have important implications for the strategy of tumor immunotherapy.

Authors

Xue-Feng Bai, Jinqing Liu, Ou Li, Pan Zheng, Yang Liu

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Molecular lesions in the P1A gene of the recurrent tumors. (a) Chromatog...
Molecular lesions in the P1A gene of the recurrent tumors. (a) Chromatograms of sequencing reactions of both cDNA and genomic PCR products. Mutations in nucleotides are indicated by arrows, while the replaced AAs are colored red. (b) Restriction enzyme mapping of the subclones isolated either from the parental J558-Neo cells or from the recurrent tumor cell lines Tum 1 and Tum 2. AvaII recognizes GGT(A)CC, which can be generated in the mutant P1A(9L); Fnu4HI is specific for GCNGC, which is present in P1A(6R). The two enzymes failed to identify any mutation in 37 clones of J558-Neo tumor cells. However, they divided the Tum 1 clones into four groups and Tum 2 clones into two groups (shown in figure as G1, G2, G3, and G4). The proportion of clones within each group is presented underneath each photograph. All suggested mutations of Tum 2 and Tum 1 and lack of mutation in J558-Neo clones were confirmed by DNA sequencing. DNA sequencing also revealed that the uncut Tum 2 G2 subclones harbored two independent mutations, P1A(7P) and P1A(8G). (c) Expression of the P1A gene in the Tum 1 G2 clones. RNA was isolated and used for RT-PCR (lane 3 and lane 4). No product was observed when the reverse transcriptase (RT) was not used (lane 5). As a comparison, PCR products from genomic DNA were also produced (lane 1 and lane 2). Note that while the genomic DNA is apparently heterozygous at P9, only P1A(9L) RNA is observed in the tumor cells. WT, wild type.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts